Code intelligence

FDA-BLA761113 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-BLA761113.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical

Critical

100%

High

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: SARCLISA (ISATUXIMAB) — Type 1 - New Molecular Entity

Policy FDA-BLA761113 · Hematology

Critical

Sarclisa (isatuximab) is an injectable CD38-directed cytolytic antibody approved for multiple myeloma, administered via intravenous injection and billing under Medicare Part B. As a hospital or office

View alert